<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LUZU- luliconazole cream </strong><br>Medicis Pharmaceutical Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LUZU safely and effectively. See full prescribing information for LUZU.<br><br>LUZU (luliconazole) Cream, 1% for topical use<br>Initial U.S. Approval: 2013</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LUZU (luliconazole) Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis caused by the organisms <span class="Italics">Trichophyton rubrum</span> and <span class="Italics">Epidermophyton floccosum</span>, in patients 18 years of age and older. (<a href="#s1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>For topical use only. Not for ophthalmic, oral, or intravaginal use. (<a href="#s2">2</a>)</li>
<li>Interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">Tinea Pedis</span>: LUZU Cream, 1% should be applied to the affected and immediate surrounding area(s) once a day for two weeks. (<a href="#s2">2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">Tinea Cruris</span> and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> Corporis: LUZU Cream, 1% should be applied to the affected skin and immediate surrounding area(s) once a day for one week. (<a href="#s2">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Cream, 1% (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#s4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions observed in clinical trials were <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>, which occurred in less than 1% of subjects. (<a href="#s6.1">6.1</a>).<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<br><br></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-5.2" class="toc">6.2	Post-Marketing Experience</a></h2>
<h1><a href="#section-6" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-9.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-9.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1	Interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">Tinea Pedis</span></a></h2>
<h2><a href="#section-11.2" class="toc">14.2	<span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">Tinea Cruris</span></a></h2>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis caused by the organisms <span class="Italics">Trichophyton rubrum</span> and <span class="Italics">Epidermophyton floccosum</span>, in patients 18 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">For topical use only. LUZU Cream, 1% is not for ophthalmic, oral, or intravaginal use.</p>
<ul>
<li>When treating interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, a thin layer of LUZU Cream, 1% should be applied to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily for two (2) weeks.</li>
<li>When treating <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span> or <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, LUZU Cream, 1% should be applied to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily for one (1) week.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Cream, 1%. Each gram of LUZU Cream, 1% contains 10 mg of luliconazole in a white cream base.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-5"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-5.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.</p>
<p>In three Phase 3 clinical trials, 616 subjects were exposed to LUZU Cream, 1%: 305 with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> and 311 subjects with <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>. Subjects with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> or <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span> applied LUZU Cream, 1% or vehicle cream once daily for 14 days or 7 days, respectively, to affected and adjacent areas. During clinical trials with LUZU Cream, 1%, the most common adverse reactions were <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> which occurred in less than 1% of subjects in both the LUZU and vehicle arms. Most adverse reactions were mild in severity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.2"></a><a name="section-5.2"></a><p></p>
<h2>6.2	Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postmarketing use of luliconazole cream, 1%: <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> and <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-6"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The potential of luliconazole to inhibit cytochrome P-450 (CYP) enzymes 1A2, 2C9, 2C19, 2D6, and 3A4 was evaluated <span class="Italics"> in vitro</span>. Based on <span class="Italics"> in vitro</span> assessment, luliconazole at therapeutic doses, particularly when applied to patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, may inhibit the activity of CYP2C19 and CYP3A4. However, no <span class="Italics"> in vivo</span> drug interaction trials have been conducted to evaluate the effect of luliconazole on other drugs that are substrates of CYP2C19 and CYP3A4.</p>
<p>Luliconazole is not expected to inhibit CYPs 1A2, 2C9 and 2D6 based on <span class="Italics"> in vitro</span> assessment. The induction potential of luliconazole on CYP enzymes has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.1.1"></a><p></p>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies of LUZU Cream, 1% in pregnant women. LUZU Cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>The animal multiples of human exposure calculations were based on daily dose body surface area (BSA) comparisons (mg/m<span class="Sup">2</span>) for the reproductive toxicology studies described in this section and in Section 13.1. The Maximum Recommended Human Dose (MRHD) was set at 8 g 1% cream per day (1.33 mg/kg/day for a 60 kg individual which is equivalent to 49.2 mg/m<span class="Sup">2</span>/day).</p>
<p>Systemic embryofetal development studies were conducted in rats and rabbits. Subcutaneous doses of 1, 5 and 25 mg/kg/day luliconazole were administered during the period of organogenesis (gestational days 7-17) to pregnant female rats. No treatment related effects on maternal toxicity or malformations were noted at 25 mg/kg/day (3 times the MRHD based on BSA comparisons). Increased incidences of skeletal variation (14th rib) were noted at 25 mg/kg/day. No treatment related effects on skeletal variation were noted at 5 mg/kg/day (0.6 times the MRHD based on BSA comparisons).</p>
<p>Subcutaneous doses of 4, 20 and 100 mg/kg/day luliconazole were administered during the period of organogenesis (gestational days 6-18) to pregnant female rabbits. No treatment related effects on maternal toxicity, embryofetal toxicity or malformations were noted at 100 mg/kg/day (24 times the MRHD based on BSA comparisons). </p>
<p>In a pre- and post-natal development study in rats, subcutaneous doses of 1, 5 and 25 mg/kg/day luliconazole were administered from the beginning of organogenesis (gestation day 7) through the end of lactation (lactation day 20). In the presence of maternal toxicity, embryofetal toxicity (increased prenatal pup mortality, reduced live litter sizes and increased postnatal pup mortality) was noted at 25 mg/kg/day. No embryofetal toxicity was noted at 5 mg/kg/day (0.6 times the MRHD based on BSA comparisons). No treatment effects on postnatal development were noted at 25 mg/kg/day (3 times the MRHD based on BSA comparisons).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether luliconazole is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LUZU Cream, 1% is administered to women who are breastfeeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of LUZU Cream, 1% in pediatric patients have not been established. The number of pediatric subjects ≥12 years of age were too small to adequately assess safety and efficacy.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of LUZU Cream, 1%, 8 percent were 65 and over, while 1.4 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LUZU (luliconazole) Cream, 1% contains 1% luliconazole, an azole antifungal agent, in a white cream for topical application.</p>
<p>Luliconazole is (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile. Its structural formula is:</p>
<p><img alt="Luliconazole Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31&amp;name=luzu-01.jpg"></p>
<p>The molecular formula is C<span class="Sub">14</span>H<span class="Sub">9</span>Cl<span class="Sub">2</span>N<span class="Sub">3</span>S<span class="Sub">2 </span>with a molecular weight of 354.28. Luliconazole is the R-enantiomer and contains one chiral center. The double bond adjacent to the dithiolane group is in the E configuration.</p>
<p>LUZU Cream, 1% contains 10 mg of luliconazole per gram of cream in a vehicle consisting of benzyl alcohol, butylated hydroxytoluene, cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">LUZU Cream, 1% is an azole antifungal [see <span class="Italics"><a href="#S12.4">Clinical Pharmacology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-9.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">At therapeutic doses, LUZU Cream, 1% is not expected to prolong QTc to any clinically relevant extent.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-9.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Luliconazole is the R enantiomer of a chiral molecule. The potential for inter-conversion between R and S enantiomers in humans has not been assessed. Information on the pharmacokinetics of luliconazole presented below refers to both R enantiomer and S enantiomer, if any, combined.</p>
<p>Luliconazole is &gt;99% protein bound in plasma.</p>
<p>In a pharmacokinetic trial, 12 subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> and 8 subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span> applied a mean daily amount of approximately 3.5 grams of LUZU Cream, 1% to the affected and surrounding areas once daily for 15 days. Plasma concentrations of luliconazole on Day 15 were measurable in all subjects and fluctuated little during the 24 hour interval. In subjects with <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, the mean ± SD of the maximum concentration (C<span class="Sub">max</span>) was 0.40 ± 0.76 ng/mL after the first dose and 0.93 ± 1.23 ng/mL after the final dose. The mean time to reach C<span class="Sub">max</span> (T<span class="Sub">max</span>) was 16.9 ± 9.39 hours after the first dose and 5.8 ± 7.61 hours after the final dose. Exposure to luliconazole, as expressed by area under the concentration time curve (AUC<span class="Sub">0–24</span> was 6.88 ± 14.50 ng*hr/mL after the first dose and 18.74 ± 27.05 ng*hr/mL after the final dose. In subjects with <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, the mean ± SD C<span class="Sub">max</span> was 4.91 ± 2.51 ng/mL after the first dose and 7.36 ± 2.66 ng/mL after the final dose. The mean T<span class="Sub">max</span> was 21.0 ± 5.55 hours after the first dose and 6.5 ± 8.25 hours after the final dose. Exposure to luliconazole, as expressed by AUC<span class="Sub">0–24</span> was 85.1 ± 43.69 ng*hr/mL after the first dose and 121.74 ± 53.36 ng*hr/mL after the final dose.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s12.4"></a><a name="section-9.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.4.1"></a><a name="section-9.4.1"></a><p></p>
<h3>Mechanism of Action</h3>
<p class="First">Luliconazole is an antifungal that belongs to the azole class. Although the exact mechanism of action against dermatophytes is unknown, luliconazole appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.4.2"></a><a name="section-9.4.2"></a><p></p>
<h3>Mechanism of Resistance</h3>
<p class="First">To date, a mechanism of resistance to luliconazole has not been described.</p>
<p>LUZU Cream, 1% has been shown to be active against most isolates of the following fungi, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#S1">INDICATIONS AND USAGE</a> section:</p>
<ul>
<li><span class="Italics">Tricophyton rubrum</span></li>
<li><span class="Italics">Epidermophyton floccosum</span></li>
</ul>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies to evaluate the carcinogenic potential of LUZU Cream, 1% have not been conducted.</p>
<p>Luliconazole revealed no evidence of mutagenic or clastogenic potential based on the results of two <span class="Italics">in vitro</span> genotoxicity tests (Ames assay and Chinese hamster lung cell chromosomal aberration assay) and one <span class="Italics">in vivo</span> genotoxicity test (mouse bone marrow micronucleus test).</p>
<p>In a fertility study in rats, subcutaneous doses of 1, 5 and 25 mg/kg/day luliconazole were administered prior to and during mating and through early pregnancy. Treatment related effects on reproductive function were noted in females (decreased live embryos and decreased corpus luteum) at 5 and 25 mg/kg/day and males (decreased sperm counts) at 25 mg/kg/day. No treatment related effects on fertility or reproductive function were noted at 1 mg/kg/day (0.1× MRHD based on BSA comparisons).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1"></a><a name="section-11.1"></a><p></p>
<h2>14.1	Interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">Tinea Pedis</span></h2>
<p class="First">The safety and efficacy of LUZU (luliconazole) Cream, 1% was evaluated in two randomized, double-blind, vehicle-controlled, multi-center clinical trials in 423 subjects with a clinical and culture-confirmed diagnosis of interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>. Subjects were randomized to receive LUZU Cream, 1% or vehicle. Subjects applied either LUZU Cream, 1% or vehicle cream to the entire area of the forefeet including all interdigital web spaces and approximately 2.5 cm (1 in) of the surrounding area of the foot once daily for 14 days.</p>
<p>The mean age of the study population was 41 years; 82% were male; 53% were White and 40% were Black or African American. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>), KOH exam and dermatophyte culture were assessed at baseline, end-of-treatment (Day 14), 2 and 4 weeks post-treatment.</p>
<p>Overall treatment success was defined as complete clearance (clinical cure and mycological cure) at 4 weeks post-treatment. LUZU Cream, 1% demonstrated completed clearance in subjects with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>. Treatment outcomes at 4 weeks post-treatment are summarized in Table 1.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Efficacy Results at 4 Weeks Post-treatment – Interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">Tinea Pedis</span></span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="2">Study 1</th>
<th class="Lrule Rrule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">LUZU Cream, 1%<br>N= 106<br>n (%)</th>
<th class="Lrule" align="center">Vehicle Cream<br>N= 103<br>n (%)</th>
<th class="Lrule" align="center">LUZU Cream, 1%<br>N= 107<br>n (%)</th>
<th class="Lrule Rrule" align="center">Vehicle Cream<br>N= 107<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Proportion of subjects who achieved both clinical cure and mycological cure</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Negative KOH and culture and at most mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and/or scaling and no <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Absence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Negative KOH and negative fungal culture</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Complete Clearance<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Lrule" align="center">28 (26%)</td>
<td class="Lrule" align="center">2 (2%)</td>
<td class="Lrule" align="center">15 (14 %)</td>
<td class="Lrule Rrule" align="center">3 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Effective Treatment<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule" align="center">51 (48%)</td>
<td class="Lrule" align="center">10 (10%)</td>
<td class="Lrule" align="center">35 (33%)</td>
<td class="Lrule Rrule" align="center">16 (15%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Clinical Cure<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Lrule" align="center">31 (29%)</td>
<td class="Lrule" align="center">8 (8%)</td>
<td class="Lrule" align="center">16 (15%)</td>
<td class="Lrule Rrule" align="center">4 (4%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Mycological Cure<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Lrule" align="center">66 (62%)</td>
<td class="Lrule" align="center">18 (18%)</td>
<td class="Lrule" align="center">60 (56%)</td>
<td class="Lrule Rrule" align="center">29 (27%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2"></a><a name="section-11.2"></a><p></p>
<h2>14.2	<span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">Tinea Cruris</span></h2>
<p class="First">The safety and efficacy of LUZU (luliconazole) Cream, 1% was evaluated in a randomized, double-blind, vehicle-controlled, multi-center clinical trial in 256 subjects with a clinical and culture confirmed diagnosis of <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>. Subjects were randomized to receive LUZU Cream, 1% or vehicle. Subjects applied either LUZU Cream, 1% or vehicle cream to the affected area and approximately 2.5 cm (1 in) of the surrounding area once daily for 7 days.</p>
<p>The mean age of the study population was 40 years; 83% were male; 58% were White and 34% were Black or African American. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>), positive KOH exam and dermatophyte culture were assessed at baseline, end-of-treatment (Day 7), 2 and 3 weeks post-treatment.</p>
<p>Overall treatment success was defined as complete clearance (clinical cure and mycological cure) at 3 weeks post-treatment. LUZU Cream, 1% demonstrated completed clearance in subjects with <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>. Treatment outcomes at 3 weeks post treatment are summarized in Table 2.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2. Efficacy Results at 3 Weeks Post-treatment - <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">Tinea Cruris</span></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">LUZU Cream, 1%<br>N= 165<br>(n %)</th>
<th class="Lrule Rrule" align="center">Vehicle Cream<br>N= 91<br>(n %)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Proportion of subjects who achieved both clinical cure and mycological cure</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Negative KOH and culture and at most mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and/or scaling and no <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Absence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt><a name="footnote-8" href="#footnote-reference-8">§</a></dt>
<dd>Negative KOH and negative fungal culture</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Complete Clearance<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td class="Lrule" align="center">35 (21%)</td>
<td class="Lrule Rrule" align="center">4 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Effective Treatment<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td class="Lrule" align="center">71 (43%)</td>
<td class="Lrule Rrule" align="center">17 (19%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Clinical Cure<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Lrule" align="center">40 (24%)</td>
<td class="Lrule Rrule" align="center">6 (7%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Mycological Cure<a name="footnote-reference-8" href="#footnote-8" class="Sup">§</a>
</td>
<td class="Lrule" align="center">129 (78%)</td>
<td class="Lrule Rrule" align="center">41 (45%)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">LUZU (luliconazole) Cream, 1% is a white cream supplied in tubes as follows:</p>
<p>  60 g (NDC 99207-850-60)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F)  [<span class="Italics">see USP Controlled Room temperature</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#FDA">FDA-approved patient labeling (Patient Information)</a></p>
<ul><li>Inform patients that LUZU Cream, 1% is for topical use only. LUZU Cream, 1% is not intended for intravaginal or ophthalmic use.</li></ul>
<p><br><br>Manufactured for:<br>Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807</p>
<p>By:<br>DPT Laboratories, Ltd., San Antonio, TX  78215</p>
<p>Rev. 08/2014<br>9386401<br>140298<br><br><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="FDA"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">LUZU (loo-zoo) (luliconazole) Cream, 1%</span></p>
<table width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" align="left">
<span class="Bold">Important information:</span> LUZU Cream is for use on skin only. Do not get LUZU Cream near or in your eyes, mouth or vagina.</td></tr></tbody>
</table>
<p><span class="Bold">What is LUZU Cream?</span></p>
<p>LUZU Cream is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>), jock <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span> (<span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>), and ringworm (<span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis) in people 18 years of age and older.</p>
<p>It is not known if LUZU Cream is safe and effective in children.</p>
<p><span class="Bold">What should I tell my doctor before using Luzu Cream?</span></p>
<p>Before using LUZU Cream, tell your doctor about all of your medical conditions, including if you:</p>
<ul>
<li>are pregnant or plan to become pregnant. It is not known if LUZU Cream will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if LUZU Cream passes into your breast milk.</li>
</ul>
<p><span class="Bold">Tell your doctor about all of the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How should I use LUZU Cream?</span></p>
<ul class="Disc">
<li>Use LUZU Cream exactly as your doctor tells you to use it.</li>
<li>If you have athlete's foot (<span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>), apply a thin layer of LUZU Cream to the affected skin areas and to about 1 inch of the surrounding healthy skin 1 time a day for 2 weeks. If you have jock <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span> (<span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>) or ringworm (<span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis), apply LUZU Cream to the affected skin areas and to about 1 inch of the surrounding healthy skin 1 time a day for 1 week.</li>
<li>Wash your hands after you apply LUZU Cream.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Luzu Cream?</span></p>
<p>LUZU Cream may cause <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> at the treatment site. <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span> may happen with LUZU Cream. Tell your doctor if you have any <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> on the areas of your skin treated with LUZU Cream.</p>
<p>These are not all the possible side effects of LUZU Cream.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">General information about the safe and effective use of LUZU Cream</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. You can ask your pharmacist or doctor for information about LUZU Cream that is written for health professionals. Do not use LUZU Cream for a condition for which it was not prescribed. Do not give LUZU Cream to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p><span class="Bold">What are the ingredients in LUZU Cream?</span></p>
<p><span class="Bold">Active ingredient:</span> luliconazole</p>
<p><span class="Bold">Inactive ingredients:</span> benzyl alcohol, butylated hydroxytoluene, cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben, polysorbate 60, propylene glycol, purified water, sorbitan monostearate.</p>
<p><br>Manufactured for:<br>Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807</p>
<p>By:<br>DPT Laboratories, Ltd., San Antonio, TX  78215</p>
<p>For more information, call 1-800-321-4576</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p><br>Rev. 08/2014<br>9386401<br>140298</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="sPDP1"></a><a name="section-15"></a><p></p>
<p class="First"><br><br><span class="Bold">PRINCIPAL DISPLAY PANEL - 60 gram Carton</span></p>
<p>NDC 99207-850-60</p>
<p><span class="Bold">LUZU<span class="Sup">™</span><br>(luliconazole) Cream, 1%</span></p>
<p><span class="Bold">For Topical Use Only</span><br>Not for ophthalmic, oral, or intravaginal use<br><span class="Bold">Keep Out of Reach of Children</span></p>
<p><span class="Bold">Rx only<br>60 g</span></p>
<div class="Figure"><img alt="LUZU 60 gram carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31&amp;name=luzu-60g-carton.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LUZU 		
					</strong><br><span class="contentTableReg">luliconazole cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:99207-850</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LULICONAZOLE</strong> (LULICONAZOLE) </td>
<td class="formItem">LULICONAZOLE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETOSTEARYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL MYRISTATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 60</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:99207-850-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:99207-850-02</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204153</td>
<td class="formItem">11/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Medicis Pharmaceutical Corp.
							(182837492)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">832224690</td>
<td class="formItem">MANUFACTURE(99207-850)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>232f3996-5eb8-4207-bc2c-e5bb2ff4e279</div>
<div>Set id: a7016010-ce43-4c09-8d21-aeb697ffed31</div>
<div>Version: 2</div>
<div>Effective Time: 20140801</div>
</div>
</div> <div class="DistributorName">Medicis Pharmaceutical Corp.</div></p>
</body></html>
